0.05Open0.05Pre Close0 Volume82 Open Interest190.00Strike Price0.00Turnover46.54%IV25.14%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0051Delta0.0005Gamma5074.80Leverage Ratio-0.0089Theta-0.0006Rho-26.03Eff Leverage0.0094Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet